Approving children's cancer drugs takes 6.5 years longer

Approving children's cancer drugs takes 6.5 years longer

(HealthDay)—For cancer drugs ultimately approved by the U.S. Food and Drug Administration, the median lag time from first-in-human to first-in-child trials is 6.5 years, according to a study published in the May issue of the European Journal of Cancer.

Dylan V. Neel, from Harvard University in Boston, and colleagues conducted a systematic analysis of time from first-in- to first-in-child trials (age of eligibility <18 years) of agents first approved by the FDA for any oncology indication from 1997 to 2017.

The researchers found that during the study period, 126 drugs were initially approved for an oncology indication. Of these, 117 were nonhormonal drugs used in further analyses. Only 5.1 percent (six drugs) had an initial approval that included children, while 12.8 percent (15 drugs) still did not have a pediatric trial. There was a median time of 6.5 years between the first-in-human trial and first-in-child trial (range 0 to 27.7 years). From initial FDA approval to the first-in-child clinical trial, the median time was −0.66 years (range −43 to +19 years). Findings were similar regardless of year of initial FDA approval, drug class, or initial approved disease indication.

"These results provide a benchmark against which to evaluate recent initiatives designed to hasten drug development relevant to children with cancer," the authors write.

One researcher disclosed financial ties to the pharmaceutical industry.

Explore further

Children with cancer wait an average of 6.5 years longer than adults to access new drugs

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2019 HealthDay. All rights reserved.

Citation: Approving children's cancer drugs takes 6.5 years longer (2019, June 12) retrieved 27 September 2021 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors